ClinicalTrials.gg
CompletedNCT00259766Updated Jan 24, 2011

SHARE - Symbicort and Health Economics in a Real Life Evaluation

A Phase 3 interventional study of Budesonide and Formoterol in Asthma, sponsored by AstraZeneca. Completed at 108 sites in Sweden. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,970
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
6th of 108
1,970 · median 124
Started
2004
with 10 others
Phase 3
51 of 110
3 open now
Registered
13th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 6th largest by enrollment of the 108 interventional ones that give a count, is one of 11 that started in 2004, is one of 51 in phase 3, and was the 13th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ,
  • asthma,
  • previously treated with glucocorticosteroids and B2-agonist

Exclusion criteria

Exclusion Criteria:

  • History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,970 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities

Secondary outcomes

  1. Number of days patients or assistant persons are absent from work due to patient's asthma

  2. Number of exacerbations and treatment failures

07

Study locations

108 sites
  • Research Site
    Akersberga, Sweden
  • Research Site
    Alingsas, Sweden
  • Research Site
    Angelholm, Sweden
  • Research Site
    Angered, Sweden
  • Research Site
    Arlov, Sweden
  • Research Site
    Arvidsjaur, Sweden
  • Research Site
    Arvika, Sweden
  • Research Site
    Atvidaberg, Sweden
  • Research Site
    Bandhagen, Sweden
  • Research Site
    Boden, Sweden
  • Research Site
    Borensberg, Sweden
  • Research Site
    Bro, Sweden
  • Research Site
    Brunflo, Sweden
  • Research Site
    Eskilstuna, Sweden
  • Research Site
    Falun, Sweden
  • Research Site
    Filipstad, Sweden
  • Research Site
    Fränsta, Sweden
  • Research Site
    Gagnef, Sweden
  • Research Site
    Grängesberg, Sweden
  • Research Site
    Gullspång, Sweden
  • Research Site
    Gärsnäs, Sweden
  • Research Site
    Göteborg, Sweden
  • Research Site
    Haby, Sweden
  • Research Site
    Halmstad, Sweden
  • Research Site
    Helsingborg, Sweden
  • Research Site
    Hisingsbacka, Sweden
  • Research Site
    Hofors, Sweden
  • Research Site
    Hollviken, Sweden
  • Research Site
    Huddinge, Sweden
  • Research Site
    Höganäs, Sweden
  • Research Site
    Iggesund, Sweden
  • Research Site
    Jarfalla, Sweden
  • Research Site
    Kalmar, Sweden
  • Research site
    Karlskoga, Sweden
  • Research Site
    Karlstad, Sweden
  • Research Site
    Katrineholm, Sweden
  • Research Site
    Kil, Sweden
  • Research Site
    Kinna, Sweden
  • Research Site
    Klippan, Sweden
  • Research Site
    Kolmården, Sweden
  • Research Site
    Kristinehamn, Sweden
  • Research Site
    Kungalv, Sweden
  • Research Site
    Kungsbacka, Sweden
  • Research Site
    Kungsör, Sweden
  • Research Site
    Landskrona, Sweden
  • Research Site
    Laxå, Sweden
  • Research Site
    Leksand, Sweden
  • Research Site
    Lerum, Sweden
  • Research Site
    Lidingö, Sweden
  • Research Site
    Likenäs, Sweden
  • Research Site
    Limhamn, Sweden
  • Research Site
    Lindome, Sweden
  • Research Site
    Linköping, Sweden
  • Research Site
    Ljungskile, Sweden
  • Research Site
    Ludvika, Sweden
  • Research Site
    Luleå, Sweden
  • Research Site
    Lund, Sweden
  • Research Site
    Malmo, Sweden
  • Research Site
    Mariefred, Sweden
  • Research Site
    Molndal, Sweden
  • Research site
    Molnlycke, Sweden
  • Research Site
    Nacka, Sweden
  • Research Site
    Norrkoping, Sweden
  • Research Site
    Norrtälje, Sweden
  • Research Site
    Nyköping, Sweden
  • Research site
    Osby, Sweden
  • Research Site
    Partille, Sweden
  • Reseearch Site
    Perstorp, Sweden
  • Research Site
    Påarp, Sweden
  • Research Site
    Saltsjo-Bo, Sweden
  • Research Site
    Sandviken, Sweden
  • Research Site
    Sjobo, Sweden
  • Research Site
    Sjuntorp, Sweden
  • Research site
    Sollentuna, Sweden
  • Research Site
    Solna, Sweden
  • Research site
    Stenstorp, Sweden
  • Research Site
    Stenungsund, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Storfors, Sweden
  • Research Site
    Stugun, Sweden
  • Research Site
    Sundbyberg, Sweden
  • Research Site
    Sundsvall, Sweden
  • Research Site
    Sunne, Sweden
  • Research Site
    Söderköping, Sweden
  • Research Site
    Trollhättan, Sweden
  • Research Site
    Trosa, Sweden
  • Research Site
    Tyresö, Sweden
  • Research Site
    Täby, Sweden
  • Research Site
    Uddevalla, Sweden
  • Research site
    Ulricehamn, Sweden
  • Research Site
    Umeå, Sweden
  • Research Site
    Uppsala, Sweden
  • Research Site
    Vallentuna, Sweden
  • Research Site
    Varberg, Sweden
  • Research Site
    Varnamo, Sweden
  • Research Site
    Vellinge, Sweden
  • Research Site
    Vännäs, Sweden
  • Research site
    Väsby, Sweden
  • Research Site
    Västervik, Sweden
  • Research Site
    Västerås, Sweden

Showing the first 100 of 108 sites. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2005
First posted
Dec 1, 2005
Start
Apr 2004
CompletionActual
May 2007
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00259766
Lead sponsor
AstraZeneca
First posted
Dec 1, 2005
Start date
Apr 2004
Completion
May 2007
Last update
Jan 24, 2011

Study contacts

AstraZeneca Symbicort Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion